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1. Introduction
Hexamethylene bis-acetamide inducible protein 1 (HEXIM1)
was initially identified as an estrogen receptor transcription
inhibitor and also down regulated by estrogen, therefore was
named EDG1 (estrogen down regulated gene 1) (Fig. 1) [1]. It could
be induced by a small molecule Hexamethylene bis-acetamide
(HMBA), which leads to the current name HEXIM1 [2,3].
HMBA is a small molecule that has been investigated by the
National Cancer Institute due to its potent anti-cancer and cell
differentiation activities [4]. HMBA induces cell differentiation via
upregulation of HEXIM1 in breast cancer cells [1–3]. However,
HMBA failed at the Phase II clinical trial because of a dose-
dependent toxicity [4]. The main toxicity is the thrombocytopenia,
which is due to the very short biological half-life of HMBA that
necessitates administration of the agent through infusion at a high
dosage [4–6].
HEXIM1 binds to 7SK snRNA, a highly abundant non-coding
RNA [7]. This complex acts as a potent inhibitor of positive
transcription elongation b (P-TEFb) and prevents elongation of RNA
Pol II generated transcripts [2,8,9] (Fig. 1). The ratio of inactive to
active P-TEFb in cells is regulated by HEXIM1/7SK snRNP, which
plays a critical role in the regulation of expression of a wide range
of genes such as estrogen and glucocorticoid receptor regulated
genes [10–12]. We also reported the inhibitory role of HEXIM1 in
Abbreviations: HEXIM1, hexamethylene bis-acetamide inducible protein 1;
HMBA, hexamethylene bis-acetamide; HSP70, heat shock protein 70; SAHA,
suberanilohydroxamic acid; HDAC, histone deacetylases; SDS/PAGE, sodium
dodecyl sulfate polyacrylamide gel electrophoresis; FBS, fetal bovine serum; PVDF,
polyvinylidene diflouride.
prostate tumorigenesis [13,14]. HEXIM1 functions as an androgen
receptor co-repressor as it physically interacts with the androgen
receptor and is required for the ability of anti-androgens to inhibit
androgen-induced target gene expression and cell proliferation
[14]. Stimulating HEXIM1 expression is a novel strategy for the
treatment of hormone dependent breast and prostate cancer.
The induction of HEXIM1 transcription by HMBA likely occurs
through the recruitment of P-TEFb to HEXIM1 promoter. Peterlin
and colleagues reported that AKT/PI3K is involved in the
phosphorylation of the elongation factor inhibitory complex,
which causes the complex to dissociate and HEXIM1 expression to
be transiently induced before the recruitment of newly formed
elongation factor inhibitory complexes [15,16]. However, the direct
molecular targets of HMBA that transiently induce HEXIM1 are not
well-defined.
In breast cells, HEXIM1 suppresses cancer metastasis by
inhibiting cell invasion, angiogenesis, and the premetastatic niche
[17]. However, HEXIM1 expression is lost during breast and
prostate tumor progression [11,14]. To enhance HEXIM1 expres-
sion, we developed polymer-mediated delivery of HMBA to
mammary tumors that resulted in increased HEXIM1 expression
and inhibited tumor metastasis. This delivery strategy did not
result in thrombocytopenia, the toxicity associated with HMBA in
clinical trials. If the druggable features of HMBA could be improved
through structural optimization, more promising drug candidates
may be developed to increase HEXIM1 expression. These new drug
candidates potentially have a broad application in hormone
dependent breast and prostate cancer treatment.
To enhance the potential translational impact of our studies, we
conducted a study that focused on the lead optimization of HMBA,
which resulted in the generation of more potent inducers of
HEXIM1 expression such as compound 4a1(Fig. 2) [18]. The finding
provides a unique unsymmetrical molecular scaffold that can
induce HEXIM1 expression in prostate and breast cancer cells, and
has opened a new lead optimization direction for HMBA [18,19].
Our results support the potential of both symmetrical and
unsymmetrical HMBA derivatives as new drug candidates.
However before we can conduct further lead optimization of
HMBA to generate more potent HEXIM1 inducers, a critical step
that needs to be taken is the identification of the molecular targets
of HMBA and the derivatives.
The detail mechanism of the induction of HEXIM1 expression
by HMBA is poorly understood, with no any known molecular
candidates for direct interaction with HMBA. The elucidation of the
target of HMBA is necessary in order to further optimize its
therapeutic potential and minimize the side effects. Target
identification will be valuable in understanding how HMBA and
derivatives act in the cells. Moreover, there may be existing
chemotherapeutic approaches or drugs that have the same
molecular target as HMBA, and thus may substitute for HMBA
in the induction of HEXIM1 expression for the treatment of cancer.
In addition, HMBA and 4a1 induce cell differentiation and is
considered less cytotoxic than the existing cancer chemothera-
peutic agents.
In the current study, we designed molecular probes based on
the structures of HMBA and its more potent analog 4a1 to pull
down the binding proteins of these compounds. Via proteomic
approaches and biological assays, we found that HMBA and 4a1
bind to heat shock protein 70 kDa (HSP70) to induce HEXIM1
expression. To the best of our knowledge, HSP70 is the first
potential molecular target of HMBA identified, which sheds light
on the upstream signaling involved in the induction of HEXIM1
expression. This finding provides a solid foundation for further
optimization to improve the therapeutic potential of HMBA, and
minimize its side effects.
2. Materials and methods
2.1. Biotinylation of 4a1 and HMBA
Chemicals were commercially available and used as received
without further purification unless otherwise noted. Moisture
sensitive reactions were carried out under a dry argon atmosphere
in pre-dried glassware. Thin-layer chromatography was performed
on pre-coated silica gel F254 plates (Whatman). Silica gel column
chromatography was performed using silica gel 60A (Merck, 230–
400 Mesh), and hexane/ethyl acetate was used as the elution
solvent. Mass spectra were obtained on the Micromass Quadrupole
Time-of-Flight (QTOF) Electrospray mass spectrometer at Cleve-
land State University MS facility Center. All the NMR spectra were
recorded on a Bruker 400 MHz in either DMSO-d6 or CDCl3.
Chemical shifts (d) for 1H NMR spectra are reported in parts per
million to residual solvent protons. The probe synthesis is
illustrated in Schemes 1 and 2. The final product characterization
is as follows.
4a1 probe: 1H NMR (400 MHz, DMSO-d6) d 7.907 (1H, t,
J = 5.2 Hz), 7.742 (2H, m), 7.137 (2H, d, J = 8.4 Hz), 6.834 (2H, d,
J = 8.4 Hz), 6.408 (1H, s), 6.343 (1H, s), 4.297 (1H, m), 4.126 (1H, m),
3.915 (2H, t, J = 6.8 Hz), 3.293 (2H, s), 3.096 (1H, m), 3.0016H, m),
2.816 (1H, dd, J = 5.2, 12.4 Hz), 2.575 (1H, d, J = 12.4 Hz), 2.047 (2H,
m), 1.779 (3H, s), 1.719–1.229 (22H, m); ESI–MS calculated for
C32H50N5O5SNa [M+Na]+: 639.3, found: 640.1
HMBA probe: 1H NMR (400 MHz, DMSO-d6) d 7.791 (1H, t,
J = 5.2 Hz), 7.749 (1H, t, J = 5.6 Hz), 6.445 (1H, s), 6.374 (1H, s), 4.298
(1H, m), 4.115 (1H, m), 3.092 (1H, m), 2.997 (4H, m), 2.817 (1H, dd,
Fig. 1. HMBA induces HEXIM1 expression and blocks estrogen receptor transcription.
Fig. 2. Structures of HMBA and 4a1.
J = 5.2, 12.4 Hz), 2.572 (1H, d, J = 12 Hz), 2.038 (2H, t, J = 7.2 Hz), 1.775
(3H, s), 1.593-1.223 (14H, m); ESI–MS calculated for
C18H32N4O3SNa [M+Na]+: 407.2, found: 406.9
2.2. Biological methods and materials
2.2.1. Cell culture
LNCaP cells were obtained from ATCC (Rockville, MD). The cells
were maintained in RPMI1640 medium supplemented with 10%
fetal bovine serum (FBS), 2 mmol/L L-Glutamine, 1 mmol/L sodium
pyruvate, 100 U/mL penicillin-streptomycin. FBS was heat inacti-
vated for 30 min in a 56 C water bath before use. Cell cultures were
grown at 37 C, in a humidified atmosphere of 5% CO2 in a Hereaus
CO2 incubator.
2.2.2. Cell viability analysis
The effects of compounds on LNCaP cell viability were assessed
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H- tetrazo-
lium bromide assay in four replicates. Cells were grown in
RPMI1640 medium in 96-well, flat-bottomed plates for 24 h, and
were exposed to various concentrations of the compounds
dissolved in DMSO (final concentration 0.1%) in media for 72 h.
Controls received DMSO vehicle at a concentration equal to that in
drug-treated cells. The medium was removed, replaced with
200 mL of 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide in fresh media, and cells were incubated
in the CO2 incubator at 37 C for 2 h. Supernatants were removed
from the wells, and the reduced 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide dye was solubilized in 200 mL/
well DMSO. Absorbance at 570 nm was determined on a plate
reader. Statistical and graphical information was determined using
GraphPad Prism software (GraphPad Software Incorporated) and
Microsoft Excel (Microsoft Corporation).
2.2.3. Cell differentiation imagines
The effects of compounds on LNCaP cell differentiation were
assessed using six well plates. Cells were grown in RPMI1640
medium in 6-well, flat-bottomed plates for 24 h, and were exposed
Scheme 1. Biotin conjugated HMBA probe.
Scheme 2. Biotin conjugated 4a1 probe.
to various concentrations of the compounds dissolved in DMSO
(final concentration 0.1%) in media for 5 days. Controls received
DMSO vehicle at a concentration equal to that in drug-treated cells.
Cell morphological images in 6-well microplate were carried out
manually on an inverted VWR VistaVision microscope (Bridgeport
NJ) equipped with VWR VistaVision camera DV-2D (10 X objective,
scan bar: 200 mm).
2.2.4. Biotin-neutravidin pull-down assay
The pull down assay was performed according to the protocol of
neutravidin (Thermofisher). LNCaP cells (1.0  107) were disrupted
in NP-40 lysis buffer and sonicated, with freshly added protease
inhibitor cocktail (Roche). The cell lysate was incubated with the
probes (final probe concentration in the lysate was 200 mM) for 1 h
at room temperature, and then incubated with neutravidin resin
for 30 mins. The mixture was loaded onto a separation column and
centrifuged. The resin was washed with binding buffer for 5 times.
The last wash elution solution was kept. The resin was further
washed with buffer containing compound 4a1 (200 mM) or HMBA
(1 mM). The last buffer without drug wash solution (lane 3 and 5)
(Fig. 5), wash solution with compound 4a1 and HMBA (lane 4 and
6), were denatured in SDS sample buffer, and separated by SDS-
PAGE. Lane 1 represents the molecular weight markers and lane 2
is the whole cell lysate. Visualization of the separated proteins with
coomassie blue stain showed the proteins bound to 4a1 or HMBA.
In addition, to the probes of HMBA and 4a1, LNCaP prostate cancer
cell lysate was also exposed to a negative probe for 1 h at room
temperature, and then incubated with neutravidin resin for 30
mins. The mixture was loaded on a separation column and
centrifuged. The resin was washed with binding buffer for 5 times.
The last wash elution solution was kept. The resin was further
washed with buffer containing HMBA (1 mM). The last buffer
without drug wash solution (lane 3), wash solution with HMBA
(lane 4), were denatured in SDS sample buffer, and separated by
SDS-PAGE. Lane 1 represents the molecular weight markers and
lane 2 is the whole cell lysate. Visualization of the separated
proteins was completed with coomassie blue staining.
2.2.5. Peptide analysis of the binding protein via mass spectrometry
Bands visualized by coomassie blue staining were cut and
transferred to 0.65 mL siliconized tubes (National Scientific Supply,
Claremont, CA, USA). Proteins were in-gel digested by trypsin
(Sequencing Grade, Modified; Promega, Madison, WI, USA). The
protein digest was reconstituted in 20 mL of 0.1% (v/v)
trifluoroacetic acid prior to LC-QTOF/MS analysis. Peptide separa-
tion was carried out using 10-mL sample injection at 50 mL/min
flow rate on a Vydac1 Protein & Peptide C18 (5 mm, 300 Å,
1 mm  150 mm) column (Grace Discovery Sciences, Deerfield, IL,
USA) proceeded by an inline filter (0.5 mm pore) (Upchurch
Scientific, Oak Harbor, WA, USA). The gradient elution profile
consisted of 1% of mobile phase A for 5 min, then brought to 60% of
mobile phase B over 90 min, and followed by 90% of mobile phase B
for 8 min. The total run time was 105 min. Mobile phase A was 0.1%
(v/v) formic acid in HPLC-grade ddH2O, and the mobile phase B was
0.1% (v/v) formic acid in HPLC-grade acetonitrile. Peptide detection
was done using the positive information-dependent-acquisition
(IDA) mode of AB Sciex QStarTM Elite Q-TOF mass spectrometer (AB
Sciex, Foster City, CA, USA). Data acquisition was performed using
AB Sciex Analyst QS (v. 2.0). Protein identification through peptides
matching was accomplished using Mascot MS/MS Ions Search
(http://www.matrixscience.com).
2.2.6. Western blot
To determine the effect of HMBA, 4a1, SW02, Pifitrin-m,
synthesized probes on the HEXIM1 expression, LNCaP cells were
treated with these chemicals or their combinations at indicated
concentrations respectively for 24 h. Total cell lysates were
extracted using M-PER reagent (Pierce). Equal amounts of proteins
(50 mg) samples were separated on 12% SDS-polyacrylmide gel and
transferred onto a polyvinylidene diflouride (PVDF) membrane
(Pall Cooperation, FL.). After blocking for 1 h, the membrane was
incubated in PBST containing 5% BSA and primary antibody specific
to HEXIM1, p21 or actin (Cell signaling, MA) overnight at 4 C. HRP-
conjugated anti-rabbit IgG or anti-mouse IgG (Cell signaling, MA)
were used as secondary antibody and incubated at room
temperature for 1 h. The membrane was incubated in ECL plus
reagent (GE health) and then exposed to hyper film. The
densitometry measurement of the band intensities of HEXIM1,
p21 and b-actin were quantified using ImageJ (NIH https://imagej.
nih.gov/ij/) and the data was used to generate the corresponding
bar figures. The normalization results are based on three
independent experiments (SD), and only one of the representa-
tive bands is presented.
2.2.7. Statistical analysis
Statistical and graphical information were determined using
GraphPad Prism software (GraphPad Software Incorporated) and
Microsoft Excel (Microsoft Corporation). Statistically significant
Fig. 3. Structures of 4a1 and HMBA probes.
differences were calculated with the two-tailed unpaired Student’s
t-test and P values reported at 95% confidence intervals.
3. Results and discussions
3.1. Construction of the biotinylated probes based on compound 4a1
and HMBA
Numerous studies have demonstrated the induction of cell
differentiation and HEXIM1 expression by HMBA [3,20]. However,
the HMBA concentrations used in these studies are in the
millimolar range. We speculate that HMBA binds to its molecular
targets with low affinity, and therefore, using HMBA to design
molecular probes to pull down its targets is not optimal, and the
potential for false positive could be high. On the other hand,
compound 4a1, a new HMBA analog developed recently, showed
increased potency in the induction of HEXIM1 expression when
compared to HMBA, perhaps due to enhanced affinity of 4a1 for its
target [18]. Thus, 4a1 may be a better molecular probe for the
identification of binding proteins of HEXIM1 inducers. Target
identification represents a major challenge in small molecule drug
development. A method used for target identification involves
immobilizing the compound via a chemical linker on a solid-phase
support, followed by affinity purification of the cellular targets.
Therefore, we designed and synthesized a biotin-linked 4a1 as the
probe for the target identification (Fig. 3).
In order to determine if the HMBA binding targets are the same
as 4a1, we synthesized an HMBA biotin-linked probe as well
(Schemes 1 and 2) to examine if the two probes would pull down
the same proteins. To test if the probes retained the biological
activity of the parental compounds HMBA and 4a1, HEXIM1
expression was examined using western blots after treatment of
cells with the probes. Treatment of LNCaP prostate cancer cells
with either biotinylated-4a1 or HMBA resulted in the induction
of HEXIM1 expression, comparable to what was observed after
treatment with parental compounds HMBA or 4a1 (Fig. 4). It
should be noted that HMBA probe concentration used was much
lower than that of HMBA due to the relatively lower solubility of
the probe. These results suggest that the linkage and biotin moiety
did not attenuate the activity of the parental compounds much,
and the compound moiety can still bind to their targets and induce
HEXIM1 expression.
3.2. Affinity purification of 4a1 and HMBA bound proteins
We hypothesize that 4a1 and HMBA bind to certain cellular
factors in order to stimulate HEXIM1 expression. Therefore, we
incubated 4a1 or HMBA probes with LNCaP cell lysates in order to
allow binding of cellular proteins to the 4a1 or HMBA moiety of the
probes, respectively. For protein isolation, the biotin moiety of the
probe was bound to the neutravidin resin to immobilize the probe.
After extensive washing with binding buffer, the non-specific
binding proteins were eluted. Then, 4a1 and HMBA were used as
competing agents to elute proteins bound to the probes. The major
steps are shown in Fig. 5A. We next examined the molecular
weight of the binding proteins using sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS/PAGE) and stained the gel
with coomassie blue reagent (Fig. 5B). Lane 2 is the whole cell
lysate, lane 3 is the final elution solution of 4a1 probe, lane 4
contains the proteins eluted with 4a1, lane 5 is the final elution of
probe HMBA, and lane 6 contains the proteins eluted with HMBA.
There are two protein bands visible in lanes 4 and 6 with molecular
weights around 70 kDa and 55 kDa respectively. The results reveal
that both probes pulled down proteins with similar molecular
weights, suggesting that HMBA and 4a1 have the same molecular
targets. While these two protein bands are the most visible ones
using our current methodology, there are likely less abundant
proteins that bind to the probes as well. We will identify the visible
proteins first and verify if they are the molecular targets of HMBA
and 4a1. In the future, we will use a more sensitive staining method
to identify the less abundant bound proteins. To rule out that the
neutravidin resin might retain non-specific and highly abundant
proteins, we also used biotin as a negative control to repeat the
same experiment (Fig. 5C). The results revealed that the negative
control probe did not pull out any visible proteins with our current
methodology. The proteins collected from the pull down assay of
the two probes are specific to HMBA and 4a1.
3.3. Identification of the bound proteins
The eluted proteins were separated by SDS/PAGE and collected
by excising visible protein bands (A-D). Several very faint bands
that are above bands A and C were also collected for analysis. The
samples were subjected to tryptic digestion in situ. The resulting
peptide mixture was identified with mass spectrometry. The
Fig. 4. Probes stimulate HEXIM1 expression in LNCaP cells. The cells were treated with DMSO, HMBA (5 mM), HMBA probe (200 mM), 4a1 (250 mM), 4a1 probe (200 mM) for
24 h. The results represent three independent experiments and the representative one or the mean is presented (SD). (A) A representative western blot result of HEXIM1
expression. (B) The densitometry measurement of the band intensities of three western blots. *P < 0.01 vs. DMSO by unpaired t test, #p < 0.05 vs DMSO by unpaired t test.
Fig. 5. Affinity isolation of 4a1 and HMBA bound proteins. (A) Procedure for the purification of 4a1 and HMBA bound proteins from LNCaP cell lysate. (B) The protein bands
pullout by the probes. Visualization of the separated proteins with coomassie blue stain showed two major the proteins bound to 4a1 or HMBA. (C) Cell lysate exposed to a
negative probe and the visualization of the separated proteins with coomassie blue stain showed no visible protein bands.
Table 1
Peptides were sequenced by electrospray ionization quadrupole time-of-flight tandem mass spectrometry, and internal sequences were searched using the Mascot Database.
Protein
band
Molecular weight
(estimated based on the
marker)
Peptides (bold and red) matching with potential protein Percentage of
the matching
Protein identity
A/C 70KD MMKFTVVAAA LLLLGAVRAE EEDKKEDVGT VVGIDLGTTY SCVGVFKNGR VEIIANDQGN
RITPSYVAFT PEGERLIGDA AKNQLTSNPE NTVFDAKRLI GRTWNDPSVQ QDIKFLPFKV
VEKKTKPYIQ VDIGGGQTKT FAPEEISAMV LTKMKETAEA YLGKKVTHAV VTVPAYFNDA
QRQATKDAGT IAGLNVMRII
NEPTAAAIAY GLDKREGEKN ILVFDLGGGT FDVSLLTIDN GVFEVVATNG DTHLGGEDFD
QRVMEHFIKL YKKKTGKDVR KDNRAVQKLR REVEKAKRAL SSQHQARIEI ESFFEGEDFS
ETLTRAKFEE LNMDLFRSTM KPVQKVLEDS DLKKSDIDEI VLVGGSTRIP KIQQLVKEFF
NGKEPSRGIN PDEAVAYGAA
VQAGVLSGDQ DTGDLVLLDV CPLTLGIETV GGVMTKLIPR NTVVPTKKSQ IFSTASDNQP
TVTIKVYEGE RPLTKDNHLL GTFDLTGIPP APRGVPQIEV TFEIDVNGIL RVTAEDKGTG
NKNKITITND QNRLTPEEIE RMVNDAEKFA EEDKKLKERI DTRNELESYA YSLKNQIGDK
EKLGGKLSSE DKETMEKAVE
EKIEWLESHQ DADIEDFKAK KKELEEIVQP IISKLYGSGG PPPTGEEDTS EKDEL
24% Human heat
shock protein
70
B/D 55KD MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY YNEATGGKYV
PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN WAKGHYTEGA ELVDSVLDVV
RKEAESCDCL QGFQLTHSLG GGTGSGMGTL LISKIREEYP DRIMNTFSVV PSPKVSDTVV
EPYNATLSVH QLVENTDETY
CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL RKLAVNMVPF
PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDAKNMM AACDPRHGRY LTVAAVFRGR
MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK TAVCDIPPRG LKMAVTFIGN STAIQELFKR
ISEQFTAMFR RKAFLHWYTG
EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
27% Bovin Tubulin
beta chain
molecular weight of the peptide mass fingerprint was used to
identify the protein via Mascot database (Matrix Science Mascot,
Boston, MA). The proteins with the best score (highest possibility)
are listed in Table 1. Bands A and C were identified to be heat shock
protein 70 kDa (HSP70), and B and D were identified to be tubulin.
The signals from the faint bands were not adequate for mass
spectrometry analyses. These proteins may either have weak
binding affinity to the probes or are expressed at low levels in
LNCaP cells. Our current probe based pull-down strategy will be
optimized to identify these weaker binding proteins in the future.
We decided to pursue the identified bands as potential targets of
HMBA and 4a1.
3.4. Biological activity of HSP70 ligands to HEXIM1 expression
We determined whether the binding of HMBA and 4a1 to HSP70
and tubulin could interfere with the functions of these two
proteins. Tubulin can be affected in two manners: Taxanes and
epothilones stabilize tubulin polymerization, whereas vinca
alkaloids, halichondrins and colchicine inhibit tubulin polymeri-
zation [21,22]. Both tubulin stabilizers and destabilizers cause cell
cycle arrest and subsequent cell apoptosis and death. HMBA and
4a1 induce cell differentiation, but do not cause cell apoptosis and
cell death. Therefore, they are less likely to be a tubulin stabilizer or
destabilizer.
HSP70 can be affected in two ways, inhibition or activation.
SW02 {4-(4-Bromophenyl)- 5-(ethoxycarbonyl)-3,4-dihydro-6-
methyl-2-oxo-1(2H)-pyrimidinebutanoic acid methyl ester} has
been demonstrated to be an HSP70 activator and Pifitrin-m (2-
phenylethynesulfonamide, PIF) has been used as an HSP70
inhibitor [23–25]. We used these two compounds as tools to
examine if HSP70 ligands could regulate HEXIM1 expression in
LNCaP cells. The results of the study could provide us indirect
evidence of whether HSP70 is involved in HEXIM1 regulation. After
Fig. 6. HSP70 ligands regulate HEXIM1 expression in LNCaP prostate cancer cells. (A) A HSP70 inhibitor and activator show opposing effects to HEXIM1 expression; (B) A
HSP70 inhibitor and an activator were antagonistic to each other to stimulate HEXIM1expression. Cells were treated with DMSO, 5 mM HMBA, 200 mM 4a1, 250 mM SW02,
25 mM PIF or their combinations with the indicated concentrations for 24 h. The results are representative of three independent experiments and the representative one or the
mean are presented (SD). The densitometry measurement of the band intensities of three western blots were listed on the right. *P < 0.01 vs. DMSO by unpaired t test,
#p < 0.05 vs DMSO by unpaired t test.
24 h treatment with compound SW02 and Pifitrin-m, we observed
that SW02 increased HEXIM1 expression whereas Pifitrin-m
decreased HEXIM1 expression (Fig. 6A). The results suggest that
activation of HSP70 enhances HEXIM1 expression, while inhibition
attenuates basal HEXIM1 expression in prostate cancer cells. To
determine if the activator and inhibitor of HSP70 could antagonize
each other, we performed combination treatments with SW02 and
Pifitrin-m. We observed that the induction of HEXIM1 expression
by SW02 is attenuated by the Pifitrin-m (Fig. 6B), and similar
phenomenon happens to 4a1 and HMBA as well. Our results
Fig. 7. HSP70 activators induce cancer cell differentiation. (A) LNCaP cells were treated with DMSO, HMBA, 4a1 or SW02 using the indicated concentrations for 24 h. P21
expression was examined with western blot. The results are representative of three independent experiments and the representative one or the mean is presented (SD). The
densitometry measurement of the band intensities of three western blots were listed on the right. *P < 0.01 vs. DMSO by unpaired t test. (B) LNCaP cells were treated with
DMSO, HMBA, 4a1 or SW02 with indicated concentrations for 5 days, and images of cell morphology were taken (10 X objective, scan bar: 200 mm).
suggest that HSP70 plays a role in the regulation of HEXIM1
expression, HSP70 is a potential target of HEXIM1 inducers, and
HMBA and 4a1 are potential HSP70 activators.
HSP70 is a well-documented molecular chaperone protein. It
can maintain the stability of its client proteins under normal
conditions and prevent stress-induced cellular damage, which is
accomplished by maintaining the appropriate protein folding,
prevention of protein aggregation, increase or decrease of
proteasomal degradation of selected proteins. HSP70 is also known
to play an important and complex role in apoptosis via interacting
with components of apoptosis pathway or activating anti-
apoptotic mediators [24,25]. HSP70 inhibitors have been well
documented to induce apoptosis in cancer cells, while the role of
HSP70 activators in cancer cells has not yet been well investigated.
Our results indicate that HSP70 activators might play a role in
regulating HEXIM1 expression, therefore affect cell differentiation.
3.5. HSP70 activators induce cell differentiation
HMBA is well known for its ability to induce cell differentiation
[26]. We hypothesized that since HMBA and its analog 4a1 are
potential HSP70 activators, other HSP70 activators could be
potential inducers of cell differentiation as well. LNCaP cells were
treated with HMBA, 4a1 or HSP70 activator SW02. The HSP70
activator did not show acute cell toxicity compared to HSP70
inhibitors, and they caused changes in cell morphology after long
term treatment (5 days), resulting in a more elongated shape
compared to the control cells (Fig. 7B) [27]. P21 protein expression
is a biomarker for cell differentiation, and all three compounds
significantly increased p21 expression compared to the control
(Fig. 7A), which is consistent with the study of HMBA and 4a1 in
breast cancer cells [19]. The results suggest that an HSP70 activator
could induce cell differentiation, which is different from what has
been reported for HSP70 inhibitors.
3.6. HSP70 activator and inhibitor show additive effect to inhibit
cancer cell growth
HSP70 inhibitors were investigated as agents that induce cell
apoptosis and therefore have potential as cancer therapeutics.
However, HSP70 activators did not show acute cytotoxicity and
have not been as well investigated as cancer therapeutic agent.
Based on our results, HSP70 activators induce cell differentiation.
Since the activators and inhibitors of HSP70 were antagonistic with
regards to the induction of HEXIM1 expression, we determined if
the same is true with regards to regulation of cancer cell
proliferation. After 72 h treatment, HMBA and 4a1 did not cause
significant decreases in cell number, and SW02 slightly decreased
cell number (Fig. 8). HSP70 inhibitor Pifitrin-m significantly
inhibited cell proliferation in a dose dependent manner. Contrary
to what we expected, when we combined Pifitrin-m with either
HSP70 activator SW02, HMBA or 4a1, we found that the activator
augmented growth inhibition by Pifitrin-m. The combination
treatment resulted in an additive effect, and is different from the
effect of the combination treatment on HEXIM1 expression. These
findings suggest that regulation of cell growth by HSP70 activators
Fig. 8. HSP70 activators and inhibitor show additive effects to inhibit cancer cell growth. LNCaP cancer cells were treated with DMSO, HMBA, 4a1, SW02, Pifitrin-m or their
combinations at the indicated concentrations for 72 h in four replicate experiments. The cell viability was evaluated with MTT assay. The results are a representative one of
three independent experiments and the mean (SD) is represented.
and inhibitors may occur independently of HEXIM1 induction. It is
likely that HSP70 has other client proteins that can regulate cell
proliferation and account for the different effects of combination
treatment on HEXIM1 expression and cell proliferation.
4. Conclusion
Tamoxifen and aromatase inhibitors are the standard treat-
ments of estrogen dependent breast cancer. However, patients
eventually develop resistance to these endocrine disrupting
agents. At this stage, estrogen receptor still plays a critical role
in cancer cell proliferation, but does not respond to these agents
[28,29]. HEXIM1 interferes with estrogen receptor in a different
mechanism compared to tamoxifen and aromatase inhibitors, and
may be able to solve the endocrine therapy resistant breast cancer
[19]. HMBA is a well-used tool drug to induce HEXIM1 expression,
but its toxicity limits the clinical application. In addition, the direct
molecular target of HMBA is unclear, which also decreases the
further drug development efforts based on this compound as the
lead.
In fact, based on the anti-cancer activity and the bipolar
moieties of HMBA, SAHA (suberanilohydroxamic acid) was
developed and identified as a HDAC (histone deacetylases)
inhibitor (Fig. 9) [26]. However, SAHA does not induce HEXIM1
expression, which suggests that the structural modification from
HMBA to SAHA altered its mechanism of action. To focus on
HEXIM1 induction as the outcome, we performed lead optimiza-
tion and evaluated new analogs using HEXIM1 expression change
as the readout. The more potent HEXIM1 inducer 4a1 with
asymmetric structure was developed based on HMBA with
symmetric moieties. To identify the molecular targets of the
agents and elucidate the mechanism of the HEXIM1 induction, we
designed and synthesized biotinylated 4a1 and HMBA as probes.
Proteins bound to the compounds were isolated, subjected to mass
spectrometric identification, and the most prevalent binding
proteins were determined to be tubulin and HSP70. Since HMBA
and 4a1 did not induce significant cell growth inhibition or
apoptosis inducing activity, it is less likely that they are tubulin
stabilizers or de-stabilizers. Further investigation revealed that the
HSP70 activator SW02 showed similar activity as HMBA and 4a1,
including induction of HEXIM1 expression and induction of cell
differentiation. In addition, HSP70 inhibitor Pifitrin-m could
antagonize the induction of HEXIM1 expression by HMBA and
4a1. These results provide indirect evidence that HMBA and 4a1 are
likely to be HSP70 activators. Although the HSP70 activation and
inhibition antagonize each other in the induction of HEXIM1
expression, HSP70 activation and inhibition are additive with
regards to cancer cell growth inhibition. It is possible that HSP70
has other targets besides HEXIM1 that can regulate cell prolifera-
tion and account for the different effects of combination treatment
on HEXIM1 expression and cell proliferation.
Conversely, HSP70 may not be the only molecular target of
HMBA and 4a1, since other proteins appear to bind to the
biotinylated compounds. Due to the low binding affinity of these
proteins to the probes or their low abundance, we are unable to
identify these other putative binding proteins currently. Studies
are now underway to further optimize 4a1 in order to generate
more potent derivatives to induce HEXIM1 expression. In addition,
we will identify the binding domain of HMBA and 4a1 on HSP70.
The binding pocket will be the basis for structure activity
relationship studies of HMBA analogs as potential HSP70
activators.
Acknowledgements
This research was supported Center for Gene Regulation in
Health and Disease (GRHD) of Cleveland State University and Ohio
Department of Development (ODOD). Chunfang Gan was sup-
ported by National Natural Science Foundation of China (No:
21562007).
References
[1] B.M. Wittmann, N. Wang, M.M. Montano, Identification of a novel inhibitor of
breast cell growth that is down-regulated by estrogens and decreased in breast
tumors, Cancer Res. 63 (16) (2003) 5151–5158.
[2] N. He, A.C. Pezda, Q. Zhou, Modulation of a P-TEFb functional equilibrium for
the global control of cell growth and differentiation, Mol. Cell. Biol. 26 (19)
(2006) 7068–7076.
[3] M. Turano, G. Napolitano, C. Dulac, B. Majello, O. Bensaude, L. Lania, Increased
HEXIM1 expression during erythroleukemia and neuroblastoma cell
differentiation, J. Cell Physiol. 206 (3) (2006) 603–610.
[4] M. Andreeff, R. Stone, J. Michaeli, C.W. Young, W.P. Tong, H. Sogoloff, T. Ervin, D.
Kufe, R.A. Rifkind, P.A. Marks, Hexamethylene bisacetamide in myelodysplastic
syndrome and acute myelogenous leukemia: a phase II clinical trial with a
differentiation-inducing agent, Blood 80 (10) (1992) 2604–2609.
[5] C.W. Young, M.P. Fanucchi, T. Declan Walsh, L. Baltzer, S. Yaldaei, Y.W. Stevens,
C. Gordon, W. Tong, R.A. Rifkind, P.A. Marks, Phase I trial and clinical
pharmacological evaluation of hexamethylene bisacetamide administration
by ten-day continuous intravenous infusion at twenty-eight-day intervals,
Cancer Res. 48 (24 Pt 1) (1988) 7304–7309.
[6] B.A. Conley, M.J. Egorin, V. Sinibaldi, G. Sewack, C. Kloc, L. Roberts, E.G.
Zuhowski, A. Forrest, D.A. Van Echo, Approaches to optimal dosing of
hexamethylene bisacetamide, Cancer Chemother. Pharmacol. 31 (1) (1992)
37–45.
[7] J.H. Yik, R. Chen, R. Nishimura, J.L. Jennings, A.J. Link, Q. Zhou, Inhibition of P-
TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the
Fig. 9. Drug development based on HMBA as a lead compound.
coordinated actions of HEXIM1 and 7SK snRNA, Mol. Cell 12 (4) (2003) 971–
982.
[8] J. Espinoza-Derout, M. Wagner, L. Salciccioli, J.M. Lazar, S. Bhaduri, E.
Mascareno, B. Chaqour, M.A. Siddiqui, Positive transcription elongation
factor b activity in compensatory myocardial hypertrophy is regulated by
cardiac lineage protein-1, Circ. Res. 104 (12) (2009) 1347–1354.
[9] A.A. Michels, A. Fraldi, Q. Li, T.E. Adamson, F. Bonnet, V.T. Nguyen, S.C. Sedore, J.
P. Price, D.H. Price, L. Lania, O. Bensaude, Binding of the 7SK snRNA turns the
HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor, EMBO J. 23 (13) (2004)
2608–2619.
[10] M.M. Montano, Y.Q. Doughman, H. Deng, L. Chaplin, J. Yang, N. Wang, Q. Zhou,
N.L. Ward, M. Watanabe, Mutation of the HEXIM1 gene results in defects
during heart and vascular development partly through downregulation of
vascular endothelial growth factor, Circ. Res. 102 (4) (2008) 415–422.
[11] N. Ogba, L.J. Chaplin, Y.Q. Doughman, K. Fujinaga, M.M. Montano, HEXIM1
regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of
cyclin D1 in mammary cells via modulation of P-TEFb, Cancer Res. 68 (17)
(2008) 7015–7024.
[12] N. Shimizu, R. Ouchida, N. Yoshikawa, T. Hisada, H. Watanabe, K. Okamoto, M.
Kusuhara, H. Handa, C. Morimoto, H. Tanaka, HEXIM1 forms a transcriptionally
abortive complex with glucocorticoid receptor without involving 7SK RNA and
positive transcription elongation factor b, Proc. Natl. Acad. Sci. U. S. A. 102 (24)
(2005) 8555–8560.
[13] E.J. Mascareno, I. Belashov, M.A. Siddiqui, F. Liu, M. Dhar-Mascareno, Hexim-1
modulates androgen receptor and the TGF-beta signaling during the
progression of prostate cancer, Prostate 72 (9) (2012) 1035–1044.
[14] I.J. Yeh, K. Song, B.M. Wittmann, X. Bai, D. Danielpour, M.M. Montano, HEXIM1
plays a critical role in the inhibition of the androgen receptor by anti-
androgens, Biochem. J. 462 (2) (2014) 315–327.
[15] X. Contreras, M. Schweneker, C.S. Chen, J.M. McCune, S.G. Deeks, J. Martin, B.M.
Peterlin, Suberoylanilide hydroxamic acid reactivates HIV from latently
infected cells, J. Biol. Chem. 284 (11) (2009) 6782–6789.
[16] X. Contreras, M. Barboric, T. Lenasi, B.M. Peterlin, HMBA releases P-TEFb from
HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription, PLoS
Pathog. 3 (10) (2007) 1459–1469.
[17] W. Ketchart, K.M. Smith, T. Krupka, B.M. Wittmann, Y. Hu, P.A. Rayman, Y.Q.
Doughman, J.M. Albert, X. Bai, J.H. Finke, Y. Xu, A.A. Exner, M.M. Montano,
Inhibition of metastasis by HEXIM1 through effects on cell invasion and
angiogenesis, Oncogene 32 (33) (2013) 3829–3839.
[18] B. Zhong, R. Lama, W. Ketchart, M.M. Montano, B. Su, Lead optimization of
HMBA to develop potent HEXIM1 inducers, Bioorg. Med. Chem. Lett. 24 (5)
(2014) 1410–1413.
[19] W. Ketchart, I.J. Yeh, H. Zhou, P.S. Thiagarajan, J. Lathia, O. Reizes, A. Exner, B. Su,
M.M. Montano, Induction of HEXIM1 activities by HMBA derivative 4a1:
functional consequences and mechanism, Cancer Lett. 379 (1) (2016) 60–69.
[20] V.M. Richon, Y. Webb, R. Merger, T. Sheppard, B. Jursic, L. Ngo, F. Civoli, R.
Breslow, R.A. Rifkind, P.A. Marks, Second generation hybrid polar compounds
are potent inducers of transformed cell differentiation, Proc. Natl. Acad. Sci. U.
S. A. 93 (12) (1996) 5705–5708.
[21] R. Bai, T.L. Nguyen, J.C. Burnett, O. Atasoylu, M.H. Munro, G.R. Pettit, A.B. Smith
3rd, R. Gussio, E. Hamel, Interactions of halichondrin B and eribulin with
tubulin, J. Chem. Inf. Model 51 (6) (2011) 1393–1404.
[22] D.G. Kingston, Tubulin-interactive natural products as anticancer agents, J.
Nat. Prod. 72 (3) (2009) 507–515.
[23] S.M. Chafekar, S. Wisen, A.D. Thompson, A. Echeverria, G.M. Walter, C.G. Evans,
L.N. Makley, J.E. Gestwicki, M.L. Duennwald, Pharmacological tuning of heat
shock protein 70 modulates polyglutamine toxicity and aggregation, ACS
Chem. Biol. 7 (9) (2012) 1556–1564.
[24] M. Granato, V. Lacconi, M. Peddis, L.V. Lotti, L. Di Renzo, R. Gonnella, R.
Santarelli, P. Trivedi, L. Frati, G. D'Orazi, A. Faggioni, M. Cirone, HSP70 inhibition
by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and
immunogenic cell death in primary effusion lymphoma, Cell. Death Dis. 4
(2013) e730.
[25] J.I. Leu, J. Pimkina, P. Pandey, M.E. Murphy, D.L. George, HSP70 inhibition by the
small-molecule 2-phenylethynesulfonamide impairs protein clearance
pathways in tumor cells, Mol. Cancer. Res. 9 (7) (2011) 936–947.
[26] V.M. Richon, S. Emiliani, E. Verdin, Y. Webb, R. Breslow, R.A. Rifkind, P.A. Marks,
A class of hybrid polar inducers of transformed cell differentiation inhibits
histone deacetylases, Proc. Natl. Acad. Sci. U. S. A. 95 (6) (1998) 3003–3007.
[27] T.C. Yuan, S. Veeramani, F.F. Lin, D. Kondrikou, S. Zelivianski, T. Igawa, D. Karan,
S.K. Batra, M.F. Lin, Androgen deprivation induces human prostate epithelial
neuroendocrine differentiation of androgen-sensitive LNCaP cells, Endocr.
Relat. Cancer 13 (1) (2006) 151–167.
[28] S.K. Guest, R. Ribas, S. Pancholi, J. Nikitorowicz-Buniak, N. Simigdala, M.
Dowsett, S.R. Johnston, L.A. Martin, Src is a potential therapeutic target in
endocrine-resistant breast cancer exhibiting low estrogen receptor-mediated
transactivation, PLoS One 11 (6) (2016) e0157397.
[29] V.C. Jordan, P. Fan, B. Abderrahman, P.Y. Maximov, Y.M. Hawsawi, P.
Bhattacharya, N. Pokharel, Sex steroid induced apoptosis as a rational
strategy to treat anti-hormone resistant breast and prostate cancer, Discov.
Med. 21 (117) (2016) 411–427.
Post-print standardized by MSL Academic Endeavors, the imprint of the Michael 
Schwartz Library at Cleveland State University, 2019
